The U.K. is more centralized than any other major power. While many in Scotland want to escape London's grip, freedom has its consequences
The most profitable private equity deal in history was badly timed but brilliantly executed
Patrick Campbell, uranium smuggler—or patsy in a Homeland Security sting?
South Korea wants its robotics industry to surpass those in Europe, Japan, and the U.S.
A ruinous Fed policy? Tell that to investors who made a trillion off Treasuries
Designers weigh in on the long-awaited Apple Watch—and wish it weren't another timid rectangle
The $182.5 million deal puts an end to years of legal wrangling
The Whitman School of Management will assign undergrads to "houses" and they'll compete for points
Women make up about 20 percent of both the entrepreneurs and investors involved in angel investment deals, up from single digits a decade ago
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.